HRH1 and melanoma: Interestingly, this combination had a similar survival advantage to IM + anti-VEGF (Figure S6F), potentially congruent, given the inhibitory effect of IM on HRH1 signaling described above, with a previous report describing better outcomes of human melanoma and lung cancers patients on ICB therapies who were concurrently receiving antihistamines (Li et al., 2022).